AACHEN, Germany--(BUSINESS WIRE)--LemnaTec GmbH (“LemnaTec”), a leader in high-throughput research platforms and analysis software for plants, today announced that it has agreed a €5 million equity investment from Anterra Capital. The proceeds from the financing will be used to accelerate LemnaTec’s continued growth and market expansion globally. This investment follows a previous financing round led by German private equity firm DEWB and underlines LemnaTec’s position as one of the largest providers of systems and software for image capture and data processing of plants and other research organisms.
“The partnership between Anterra and LemnaTec will help accelerate our expansion, particularly in the USA, and allow us to extend our software and service capabilities,” said Dirk Vandenhirtz, CEO and founder of LemnaTec. “We are now backed by two strong institutional investors and I am very confident that Anterra will energetically support our continued growth with their technology expertise and extensive industry contacts.”
Dudley Hawes, a Partner at Anterra Capital, said, “Our investment in LemnaTec provides a platform for the company to grow and support its already global customer base. We see tremendous potential in LemnaTec’s data and bioinformatics tools and believe that the company will contribute massively to the infrastructure needed to better connect and use genotyping and phenotyping information. We look forward to working with the team to strengthen operations and realise LemnaTec’s significant potential.”
LemnaTec sells hardware and software for taking digital images of plants and for processing those images to produce phenotypic data. LemnaTec’s products are designed to improve the performance of phenotyping results in R&D and this is done using a range of products - low throughput systems for lab monitoring, high throughput systems for monitoring thousands of plants in a greenhouse or systems suitable for research in open fields. LemnaTec has also developed a suite of software tools for plant phenotyping covering image acquisition, image processing and data mining to help attaining a desired phenotype for any given condition.
Announcement of this financing follows several notable achievements by LemnaTec in recent months including opening an office in St. Louis, USA and starting construction of a high output field based phenotyping facility in the UK. For further information please visit www.lemnatec.com